Although early peaks in IL-6 and monocyte MCP-1 within 0–9 h were predictive of adverse outcome, Jenkins et al. described a second peak in IL-6 and macrophage inflammatory protein (MIP)-1 alpha in HT patients who went on to have a good outcome [6]. This evidence concerns the gene IL6 and hematocrit.